Trials / Conditions / Unresectable or Metastatic Melanoma

Unresectable or Metastatic Melanoma

7 registered clinical trials studyying Unresectable or Metastatic Melanoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of ST-1898 for Unresectable or Metastatic Melanoma NCT06359860	Beijing Scitech-Mq Pharmaceuticals Limited	Phase 1 / Phase 2
Unknown	Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma NCT05783882	Biocad	Phase 3
Active Not Recruiting	Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Me NCT04674683	HUYABIO International, LLC.	Phase 3
Terminated	PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy i NCT03993379	CytomX Therapeutics	Phase 2
Terminated	NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma NCT01810016	Ludwig Institute for Cancer Research	Phase 1
Completed	Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanc NCT01844505	Bristol-Myers Squibb	Phase 3
Completed	A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in NCT01721746	Bristol-Myers Squibb	Phase 3